Objective:To investigate the effects of brachytherapy with computed tomography-guided percutaneous radioactive 1-125 seeds interstitial implantation(ISI) synchronized chemotherapy and Chinese medicine(CM) for the treatment of advanced stage of non-small cell lung cancer(NSCLC).Methods:Ninety patients diagnosed with NSCLC by biopsy were randomly assigned to three groups:the synchronized therapy group(A),the chemotherapy plus CM-treated group(B),and the chemotherapy-treated group(C);a 2-month course of treatment was administered to them all.The effectiveness of treatment was evaluated based on tumor size,tumor markers(carcinoembryonic,squamous cell carcinoma-associated antigen,and cytokeratin 19 fragment),clinical symptoms,and quality of life(QOL) in patients.Results:The total effective rates of Groups A to C were 83.33%,46.67%,and 43.33%,respectively.The tumor markers were reduced obviously in Group A,showing significant difference compared with those in the other two groups.Additionally,QOL was elevated and cancer-related symptoms were alleviated more significant in Group A than those in Group C(all P<0.05). Conclusion:The synchronized therapy of 1-125 implantation with chemotherapy and CM was a safe therapeutic method and can be regarded as a new mode for treatment of advanced-stage NSCLC. Objective: To investigate the effects of brachytherapy with computed tomography-guided percutaneous radioactive 1-125 seeds interstitial implantation (ISI) synchronized chemotherapy and Chinese medicine (CM) for the treatment of advanced stage of non-small cell lung cancer (NSCLC) .Methods : Ninety patients diagnosed with NSCLC by biopsy were randomly assigned to three groups: the synchronized therapy group (A), the chemotherapy plus CM-treated group (B), and the chemotherapy-treated group (C); a 2-month course of treatment was administered to them all. the effectiveness of treatment was based on tumor size, tumor markers (carcinoembryonic, squamous cell carcinoma-associated antigen, and cytokeratin 19 fragment), clinical symptoms, and quality of life (QOL) in patients. Results : The total effective rates of Groups A to C were 83.33%, 46.67%, and 43.33%, respectively. The tumor markers were reduced obviously in Group A, showing significant difference compared with those in the other two groups. Additionall Q: The synchronized therapy of 1-125 implantation with chemotherapy and CM was a safe therapeutic method and can be regarded as a new mode for treatment of advanced-stage NSCLC.